No Data
No Data
8-K: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals 1Q Rev $0.00 >CTXR
Citius Pharmaceuticals 1Q Loss/Shr $1.30 >CTXR
10-Q: Q1 2025 Earnings Report
Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Express News | Citius Pharma Announces LYMPHIR Is Approved By The FDA For The Treatment Of Adult Patients With Relapsed Or Refractory Stage 1-3 Cutaneous T-Cell Lymphoma
萬軍無兵策天鳳 : Summary: There is no hope left.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
71079745 萬軍無兵策天鳳 : There is hope, there is hope, do not be too pessimistic, we simply won't buy it.